One-Time Gene Editing Cut LDL Cholesterol in Half for a Year — and It's Not a Pill

A small gene-editing study published August 28, 2026 reported that a single infusion cut LDL cholesterol by up to 50 percent, and the drop held a full year later (New York Times, 2026). The therapy, from CRISPR Therapeutics, edits the PCSK9 gene inside liver cells using a one-time IV infusion. It is not a pill you take every day, and it is not a twice-yearly injection like inclisiran. Here is what the trial actually showed, who could qualify, and what the long-term unknowns are.

Key Takeaways

• A single infusion of an in-body CRISPR therapy cut LDL cholesterol by up to roughly 50 percent, with the effect sustained at 12 months in a small phase 1b trial (CRISPR Therapeutics, NEJM, 2026).
• The therapy edits the PCSK9 gene inside liver cells, the same gene that PCSK9 inhibitors and inclisiran target with repeated dosing.
• It is not yet FDA-approved, and long-term safety data beyond one year are limited. This is research-stage, not a replacement for statins.
• The price is unknown, but gene-editing therapies for sickle cell disease launched above $2 million, signaling that cost will be a major access issue if approval comes.

How the Therapy Works

The therapy, called CTX320, is delivered as a single IV infusion. It uses lipid nanoparticles — the same delivery technology used in mRNA COVID vaccines — to carry CRISPR machinery into liver cells. Once inside, the therapy finds the PCSK9 gene and disables it (NEJM, 2026).

Citation capsule: CTX320 is a single IV infusion that uses lipid nanoparticles to deliver CRISPR machinery into liver cells, where it disables the PCSK9 gene (NEJM, 2026).

Because liver cells make most of the body's PCSK9 protein, disabling the gene lowers the amount of PCSK9 in the bloodstream. With less PCSK9, more LDL receptors on liver cells pull LDL cholesterol out of circulation. The result is lower LDL.

For context, see our enlicitide oral PCSK9 guide — enlicitide is also a PCSK9-targeting drug, but it is a daily pill rather than a one-time gene edit.

What the Trial Actually Showed

The published phase 1b trial enrolled 15 participants with familial hypercholesterolemia or established cardiovascular disease who could not reach LDL targets on standard therapy (NEJM, 2026). Key results at 12 months:

Outcome	Result at 12 months
LDL cholesterol reduction	40 to 55 percent from baseline
Triglyceride reduction	Modest, around 15 percent
Adverse events	Mostly mild infusion reactions; no serious off-target events reported to date
Durability	Effect maintained across full 12-month follow-up window

Citation capsule: In a 15-person trial, a single CTX320 infusion cut LDL cholesterol by 40 to 55 percent at 12 months with no serious off-target events reported (CRISPR Therapeutics, NEJM, 2026).

The numbers matter because earlier PCSK9-targeting drugs — evolocumab and inclisiran — produce similar LDL drops but require repeated injections every two weeks or every six months. A single infusion that lasts a year or longer would change the practicality of aggressive LDL lowering, particularly for patients who struggle with injections or adherence.

For a deeper dive on LDL targets and the new2026 cholesterol rules, see our Lp(a) cholesterol test guide and the 2026 cholesterol guideline update.

Who Could Qualify — and When

CTX320 is investigational in 2026. The most likely first FDA approval, if data continue to hold, would target:

• Adults with heterozygous familial hypercholesterolemia who cannot reach LDL targets on maximally tolerated statin plus ezetimibe
• Adults with established atherosclerotic cardiovascular disease and LDL persistently above 70 mg/dL on standard therapy
• Possibly later, homozygous familial hypercholesterolemia, where LDL is much higher from birth

For most people with mild-to-moderate LDL elevations, the appropriate therapy in 2026 is still a statin. See our statin muscle pain guide and statin myths guide for the tradeoffs that drive real-world nonadherence.

How This Differs From Statins, Enlicitide, and Inclisiran

The LDL-lowering toolkit has been growing quickly. A quick comparison:

Therapy	Mechanism	Dosing	Approximate LDL reduction
High-intensity statin	Blocks cholesterol synthesis, upregulates LDL receptors	Daily pill	40 to 55 percent
Ezetimibe	Blocks cholesterol absorption	Daily pill	15 to 20 percent
Evolocumab / alirocumab	PCSK9 monoclonal antibody	Injection every 2 weeks	50 to 60 percent
Inclisiran	Small interfering RNA against PCSK9	Injection every 6 months	45 to 55 percent
Enlicitide (oral PCSK9)	Oral peptide blocking PCSK9 protein	Daily pill	45 to 55 percent
CTX320 (CRISPR)	One-time gene editing of PCSK9	Single IV infusion	40 to 55 percent (early data)

Citation capsule: Gene editing of PCSK9 produces LDL reductions similar to existing PCSK9 inhibitors, but the dosing collapses from daily or twice-monthly to a single infusion (NEJM, 2026).

The difference is dosing pattern, not efficacy ceiling. CTX320's advantage, if approved, would be adherence: one infusion a year (or potentially longer) replaces a daily pill or twice-monthly injection.

What the Long-Term Unknowns Are

The excitement is real, but so are the gaps. Five things are not yet known:

1. Durability beyond a year — gene edits are intended to be permanent, but liver cells turn over. Whether the effect lasts five years or twenty is not yet established.
2. Off-target editing — CRISPR can occasionally cut DNA at unintended sites. The 15-person trial did not detect serious off-target events, but larger trials are needed.
3. Re-dosing — if the LDL effect fades, can the therapy be repeated safely? The body's immune response to the lipid nanoparticle delivery system may complicate re-dosing.
4. Cost and access — the only FDA-approved in-body gene-editing therapy, Casgevy for sickle cell disease, launched above $2 million. Even if CTX320 is approved, list price is unlikely to be under six figures.
5. Comparison with proven therapies — long-term outcome trials showing fewer heart attacks and deaths are not yet complete. Existing LDL-lowering drugs have decades of outcome data; CTX320 has months.

What to Do Now if Your LDL Is High

If you are not in a clinical trial, your treatment ladder in 2026 still looks like this:

1. Confirm cardiovascular risk with your clinician using the new PREVENT calculator from the 2026 ACC/AHA guideline.
2. Start or optimize a high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg).
3. Add ezetimibe if LDL is not at goal.
4. Discuss PCSK9 inhibition (evolocumab or inclisiran) or oral enlicitide if available, if LDL is still above target.
5. Ask whether a CTX320 clinical trial site is geographically feasible for you. CRISPR Therapeutics maintains a public trial locator; the New England Journal editorial accompanying the 2026 paper also lists enrollment sites.

For specific guidance on statin side effects, see our statin switching guide.

Frequently Asked Questions

Is CTX320 approved by the FDA?

Not yet. CTX320 is in clinical trials. The August 2026 NEJM publication reported phase 1b results at 12 months. Approval is likely years away.

Could gene editing replace statins?

Not soon. Statins are inexpensive, well understood, and proven to prevent heart attacks over 20+ years of outcome trials. Gene editing is a single high-cost intervention whose long-term outcomes are still being measured.

Will my insurance cover it?

CTX320 is not yet sold. If approved, the price is likely to be in the six-figure range. Coverage decisions will depend on cost-effectiveness analyses and whether outcomes data accumulate.

Are there alternatives that also lower LDL by 50 percent?

Yes. Evolocumab and inclisiran, both already approved, lower LDL by similar amounts with repeated dosing. The difference is one infusion per year versus ongoing injections.

Conclusion

A single CRISPR infusion lowered LDL by roughly half for a year in a small 15-person trial — a remarkable result that opens a new chapter in cardiovascular medicine. The therapy is not a replacement for statins, and questions about durability, off-target effects, and long-term outcomes remain. For most patients in 2026, the practical path is still statin plus add-on therapy if needed; for those with severe genetic or treatment-resistant disease, gene-editing trials offer an early look at what the future may hold.

Sources

• CRISPR Therapeutics. CTX320 phase 1b LDL-C reduction one-year follow-up. New England Journal of Medicine. August 28, 2026. Retrieved September 2, 2026. https://www.nejm.org
• Johnson CY. An Experimental Single-Time Treatment Slashed Cholesterol for a Year. New York Times. August 28, 2026. Retrieved September 2, 2026. https://www.nytimes.com/2026/08/28/science/an-experimental-single-time-treatment-slashed-cholesterol-for-a-year.html
• American Heart Association. Scientific statement on emerging lipid-lowering therapies. Circulation. 2026.
• ACC/AHA. 2026 Guideline on the Management of Dyslipidemia. Circulation. 2026.